Targets › GPER
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2029.
G protein-coupled estrogen receptor that binds to 17-beta-estradiol (E2) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Stimulates cAMP production, calcium mobilization and tyrosine kinase Src inducing the release of heparin-bound epidermal growth factor (HB-EGF) and subsequent transactivation of the epidermal growth factor receptor (EGFR), activating…. (UniProt, Q99527)
Open in Phaseline: the race on GPER, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Linnaeus Therapeutics | LNS8801 G protein-coupled estrogen receptor (GPER) agonist | GPER | Phase 2 | Melanoma (Skin Cancer); Solid Tumor, Adult | Feb 2029 |
Melanoma (Skin Cancer) (1) Solid Tumor, Adult (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.